Astria Therapeutics (ATXS)
(Delayed Data from NSDQ)
$11.93 USD
-0.02 (-0.17%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $11.93 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATXS 11.93 -0.02(-0.17%)
Will ATXS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ATXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATXS
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
Is a Surprise Coming for Astria Therapeutics (ATXS) This Earnings Season?
ATXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Suncor (SU) Q3 Earnings Preview: What Investors Need to Know
Will NexTier Merger Boost Patterson-UTI's (PTEN) Q3 Earnings?
Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug
Other News for ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field
ATXS Crosses Above Key Moving Average Level
Astria Therapeutics Shareholders Meeting Decisions and Elections
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)